Market Research Logo

Global High Throughput Process Development Market Insights, Opportunity Analysis, Market Shares and Forecast 2017 - 2023

Global High Throughput Process Development Market Insights, Opportunity Analysis, Market Shares and Forecast 2017 - 2023

High throughput process development is a platform that is used to reduce the development and processing time of various biological and biomedical processes. This is widely deployed by biotechnology and pharmaceutical industries due to its several advanatages such as robust and scalable processing, time saver, highly efficient etc. The global high throughput process development market is expected to grow at a CAGR of 15% during the forecast period.

North America is the leading market region for high throughput process development market and had for accounted for the largest market revenue share in 2016. The key factors boosting the growth of global high throughput process development market in North America region is the rising expenditure on R&D infrastructure by the pharmaceutical and biopharmaceutical industries. Moreover, there is increasing demand for technologically advanced tools to enhance the production quality of biological materials in North America. Furthermore, the presence of major biotechnology and pharmaceutical industries in United States are driving the market growth. Asia-Pacific region is anticipated to be the fasting growing market region and is expected to grow at the highest CAGR during the forecast period 2016-2023. The key factors owing to this growth are the increasing governmental financial support in developing APAC countries such as India, Japan and China etc. The increased adoption of high throughput process development tools is driving the market growth in Asia Pacific region.

The global high throughput process development market is influenced by the presence of leading biotech and pharmaceutical companies such as Danaher Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Merck Millipore, Agilent technologies Inc. etc. Product launch, joint ventures, merger and acquisition are some of the crucial strategies adopted by the key market players to gain competitive advantage.

Global high throughput process development market report covers segmentation analysis of products and services, molecule type, process type and end user. Report further covers segments of products and services which include consumables & reagents, instruments and software & services. The software and services is the leading segment due to the increased adoption of high throughput process development tools and software in order to facilitate process development of pharmaceutical and biomedical products. Report further covers segments of molecule type which includes monoclonal antibodies, vaccines, recombinant insulin, and human growth hormones etc. The monoclonal antibodies are the largest molecule type segment and had accounted for the largest market revenue share in 2016. The key factor driving the segment growth is the increased adoption of targeted immunotherapy and the increasing number of therapeutic monoclonal antibodies approved by U.S. FDA . Report further covers segments of process type; the market is segmented into upstream processing and downstream processing. The downstream processing is the leading segment and had accounted for largest market revenue share in 2016 due to the increasing demand of purified biosimilars, whereas the end user includes contract manufacturing organizations and biopharmaceutical manufacturers.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIEW
2.1. GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360-DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS AND TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. INCREASING R&D EXPENDITURE
3.1.2. TECHNOLOGICAL ADVANCEMENTS IN PROCESS DEVELOPMENT
3.1.3. GROWTH IN THE BIOPHARMACEUTICAL INDUSTRY
3.1.4. GROWING PRESSURE TO LOWER THE COST OF MANUFACTURING
3.2. MARKET RESTRAINTS
3.2.1. HIGH COST OF ADVANCED HIGH THROUGHPUT PROCESS DEVELOPMENT TECHNOLOGIES
3.2.2. LACK OF SKILLED PROFESSIONALS
3.3. MARKET OPPORTUNITIES
3.3.1. OUTSOURCING TO CONTRACT MANUFACTURING ORGANIZATIONS
3.3.2. ADOPTION OF QUALITY BY DESIGN(QBD) PRINCIPLES
3.4. MARKET CHALLENGES
3.4.1. LACK OF ADEQUATE INFRASTRUCTURAL FACILITIES
3.4.2. COMPLICATED PROCESS
4. MARKET SEGMENTATION
4.1. GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY PRODUCT AND SERVICES
4.1.1. MARKET DEFINITION AND SCOPE
4.1.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.4. OPPORTUNITY MATRIX
4.1.5. MARKET SEGMENTATION
4.1.5.1. GLOBAL CONSUMABLES AND REAGENTS MARKET
4.1.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.1.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.1.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.1.4. KEY CONCLUSIONS
4.1.5.2. GLOBAL INSTRUMENTS MARKET
4.1.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.2.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.1.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.2.4. KEY CONCLUSIONS
4.1.5.3. GLOBAL SOFTWARE AND SERVICES MARKET
4.1.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.5.3.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.1.5.3.3. TOP PLAYERS & KEY PRODUCTS
4.1.5.3.4. KEY CONCLUSIONS
4.2. GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY MOLECULE TYPE
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. GLOBAL MONOCLONAL ANTIBODIES MARKET
4.2.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.2.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.4. KEY CONCLUSIONS
4.2.5.2. GLOBAL VACCINES MARKET
4.2.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.2.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.4. KEY CONCLUSIONS
4.2.5.3. GLOBAL RECOMBINANT INSULIN MARKET
4.2.5.3.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.2.5.3.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.3.4. KEY CONCLUSIONS
4.2.5.4. GLOBAL HUMAN GROWTH HORMONES MARKET
4.2.5.4.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.2.5.4.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.4.4. KEY CONCLUSIONS
4.2.5.5. GLOBAL OTHER MOLECULESMARKET
4.2.5.5.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.2.5.5.3. TOP PLAYERS & KEY PRODUCTS
4.2.5.5.4. KEY CONCLUSIONS
4.3. GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY PROCESS
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION
4.3.5.1. GLOBAL DOWNSTREAM PROCESSING MARKET
4.3.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.3.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.1.4. KEY CONCLUSIONS
4.3.5.2. GLOBAL UPSTREAM PROCESSING MARKET
4.3.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.3.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.3.5.2.4. KEY CONCLUSIONS
4.4. GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY END USER
4.4.1. MARKET DEFINITION AND SCOPE
4.4.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.4.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.4.4. OPPORTUNITY MATRIX
4.4.5. MARKET SEGMENTATION
4.4.5.1. GLOBAL BIOPHARMACEUTICAL MANUFACTURERS MARKET
4.4.5.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.1.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.4.5.1.3. TOP PLAYERS & KEY PRODUCTS
4.4.5.1.4. KEY CONCLUSIONS
4.4.5.2. GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET
4.4.5.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.4.5.2.2. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
4.4.5.2.3. TOP PLAYERS & KEY PRODUCTS
4.4.5.2.4. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECAST 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1. DANAHER CORPORATION (U.S.)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. GE HEALTHCARE (UK )
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.2.6. STRATEGIC ANALYSIS
7.3. THERMO FISHER SCIENTIFIC INC. (U.S.)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.3.6. STRATEGIC ANALYSIS
7.4. MERCK MILLIPORE (U.S.)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.4.6. STRATEGIC ANALYSIS
7.5. BIO-RAD LABORATORIES, INC. (U.S.)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.5.6. STRATEGIC ANALYSIS
7.6. AGILENT TECHNOLOGIES, INC. (U.S.)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.6.6. STRATEGIC ANALYSIS
7.7. SUN PHARMA (INDIA)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.7.6. STRATEGIC ANALYSIS
7.8. EPPENDORF AG (GERMANY)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.8.6. STRATEGIC ANALYSIS
7.9. PERKINELMER, INC. (U.S.)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.9.6. STRATEGIC ANALYSIS
7.10. SARTORIUS STEDIM BIOTECH (FRANCE)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.10.6. STRATEGIC ANALYSIS
7.11. TECAN GROUP LTD. (SWITZERLAND)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. AMGEN INC. (U.S.)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13. CELGENE CORPORATION (U.S.)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.13.6. STRATEGIC ANALYSIS
7.14. BIOGEN INC. (U.S.)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. ILLUMINA INC. (U.S.)
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
LIST OF TABLES
GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY PRODUCTS AND SERVICES ($ MILLION)
GLOBAL CONSUMABLES & REAGENTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL INSTRUMENTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL SOFTWARE & SERVICES MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY MOLECULE TYPE ($ MILLION)
GLOBAL MONOCLONAL ANTIBODIES MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL VACCINES MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL RECOMBINANT INSULIN MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL HUMAN GROWTH HORMONES MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL OTHER MOLECULES MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY PROCESS ($ MILLION)
GLOBAL DOWNSTREAM PROCESSING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL UPSTREAM PROCESSING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET BY END USERS ($ MILLION)
GLOBAL BIOPHARMACEUTICAL MANUFACTURERS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET BY GEOGRAPHY ($ MILLION)
NORTH AMERICA HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
EUROPE HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
ASIA PACIFIC HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
REST OF THE WORLD HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
LIST OF FIGURES
GLOBAL HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
GLOBAL CONSUMABLES & REAGENTS MARKET ($ MILLION)
GLOBAL INSTRUMENTS MARKET ($ MILLION)
GLOBAL SOFTWARE & SERVICES MARKET ($ MILLION)
GLOBAL MONOCLONAL ANTIBODIES MARKET ($ MILLION)
GLOBAL VACCINES MARKET ($ MILLION)
GLOBAL RECOMBINANT INSULIN MARKET ($ MILLION)
GLOBAL HUMAN GROWTH HORMONES MARKET ($ MILLION)
GLOBAL OTHER MOLECULES MARKET ($ MILLION)
GLOBAL DOWNSTREAM PROCESSING MARKET ($ MILLION)
GLOBAL UPSTREAM PROCESSING MARKET ($ MILLION)
GLOBAL BIOPHARMACEUTICAL MANUFACTURERS MARKET ($ MILLION)
GLOBAL CONTRACT MANUFACTURING ORGANIZATIONS MARKET ($ MILLION)
UNITED STATES (U.S.) HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
CANADA HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
UNITED KINGDOM (UK) HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
FRANCE HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
GERMANY HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
SPAIN HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
ROE HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
INDIA HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
CHINA HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
JAPAN HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
AUSTRALIA HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
ROAPAC HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
LATIN AMERICA HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET ($ MILLION)
MENA HIGH THROUGHPUT PROCESS DEVELOPMENT MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report